ASH news: proteasome inhibitor LDP-341 as attractive new drug for multiple myeloma, CLL Dec. 11, 2000
Early clinical evidence of efficacy, safety of UCN-01 plus fludarabine phosphate in CLL Dec. 11, 2000
Atrix completes phase III study of 1-month Leuprogel formulation in advanced prostate cancer Dec. 7, 2000
Data presented at AHS meeting support further development of G-3139 in combination regimens Dec. 7, 2000
Tezacitabine, an antimetabolite nucleoside analogue, assessed in hematological malignancies Dec. 7, 2000
RSS